PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance. Tumour cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system. Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma. Although it is well established that PD-1-PD-L1 blockade activates T cells, little is known about the role that this pathway may have in tumour-associated macrophages (TAMs). Here we show that both mouse and human TAMs express PD-1. TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers. TAM PD-1 expression correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion. This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and treatment with checkpoint inhibitors targeting PD-1 or PD-L1 increases phagocytosis and reduces tumor growth [329].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“In human and mouse CRC tumor models, high levels of PD-1 expression on TAM have low tumor phagocytosis”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“Tumor-associated macrophages were also recently shown to express PD-1 in both mice and humans with colorectal cancer and to impair macrophage phagocytosis (59).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Cited by
Items 301–400 of 1,001
The application of HER2 and CD47 CAR-macrophage in ovarian cancer
Chen, Y., Zhu, X., Liu, H., Wang, C., Chen, Y., Wang, H., Fang, Y., Wu, X., Xu, Y., Li, C., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04479-8 · Cited by 115
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
“In addition to T cells, PD-1 is also expressed on natural killer cells, macrophages, and dendritic cells, which are enriched in the tumor microenvironment (Karyampudi et al., 2016; Gordon et al., 2017; Hsu et al., 2018; Mariotti et al., 2019).”
BackgroundFcγ receptors and immunomodulatory antibodies in cancer
Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 104
The role of macrophage phenotype in regulating the response to radiation therapy
Shi, X., & Shiao, S. L. (2017) · Translational research · doi:10.1016/j.trsl.2017.11.002 · Cited by 102
Tamiya, M., Tamiya, A., Inoue, T., Kimura, M., Kunimasa, K., Nakahama, K., Taniguchi, Y., Shiroyama, T., Isa, S., Nishino, K., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192227 · Cited by 98
Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy
Evrard, D., Szturz, P., Tijeras‐Raballand, A., Astorgues‐Xerri, L., Abitbol, C., Paradis, V., Raymond, É., Albert, S., Barry, B., & Faivre, S. J. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.10.040 · Cited by 104
Fiegle, E., Doleschel, D., Koletnik, S., Rix, A., Weiskirchen, R., Borkham‐Kamphorst, E., Kiessling, F. M., & Lederle, W. (2019) · Neoplasia · doi:10.1016/j.neo.2019.07.006 · Cited by 106
Zhu, Y.-H., Zheng, J.-H., Jia, Q.-Y., Duan, Z., Yao, H., Yang, J., Sun, Y., Jiang, S.-H., Liu, D., & Huo, Y. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00741-1 · Cited by 111
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
Versteven, M., den Bergh, J. M. J. V., Marcq, E., Smits, E., Tendeloo, V. F. V., Hobo, W. A., & Lion, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00394 · Cited by 104
Regulation of Immune Cell Functions by Metabolic Reprogramming
Kim, J. (2018) · Journal of Immunology Research · doi:10.1155/2018/8605471 · Cited by 108
Cabrales, P. (2019) · Translational Oncology · doi:10.1016/j.tranon.2018.12.001 · Cited by 98
Aging, immune senescence, and immunotherapy: a comprehensive review
Elias, R., Hartshorn, K., Rahma, O., Lin, N., & Snyder-Cappione, J. E. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.08.006 · Cited by 96
Emerging Role of PD-1 in the Central Nervous System and Brain Diseases
Zhao, J., Roberts, A., Wang, Z., Savage, J. T., & Ji, R. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00683-y · Cited by 119
The immune landscape of common CNS malignancies: implications for immunotherapy
Ott, M., Prins, R. M., & Heimberger, A. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00518-9 · Cited by 95
Lymphatic PD-L1 expression restricts tumor-specific CD8+ T-cell responses
Cousin, N., Cap, S., Dihr, M., Tacconi, C., Detmar, M., & Dieterich, L. C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0633 · Cited by 95
“Lymphatic PD-L1 does not affect DC activation nor myeloid infiltrates APCs such as DCs have been shown to express PD-1 (24, 25), and may receive inhibitory signals from PD-L1þ LECs as they migrate from the tumor microenvironment to draining LNs.”
BackgroundKim, H. R., Park, H. J., Son, J., Lee, J. G., Chung, K. Y., Cho, N. H., Shim, H. S., Park, S., Kim, G., Yoon, H. I., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0785-8 · Cited by 107
XBP1 regulates the protumoral function of tumor-associated macrophages in human colorectal cancer
Zhao, Y., Zhang, W., Huo, M., Wang, P., Liu, X., Wang, Y., Li, Y., Zhou, Z., Xu, N., & Zhu, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00761-7 · Cited by 104
Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy
Qiao, X., Hu, Z., Xiong, F., Yang, Y., Peng, C., Wang, D., & Li, X. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01807-1 · Cited by 103
Zhang, S., Peng, W., Wang, H., Xiang, X., Ye, L., Wei, X., Wang, Z., Xue, Q., Chen, L., Yuan, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007441 · Cited by 105
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma
Brennan, K., Shin, J. H., Tay, J. K., Prunello, M., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-17298-x · Cited by 95
Liu, B., Guo, H., Xu, J., Qin, T., Guo, Q., Gu, N., Zhang, D., Qian, W., Dai, J., Hou, S., et al. (2018) · mAbs · doi:10.1080/19420862.2017.1409319 · Cited by 94
Chen, J., Zheng, D.-X., Yu, X.-J., Sun, H.-W., Xu, Y.-T., Zhang, Y., & Xu, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1652540 · Cited by 98
Su, Y., Chen, L., Yang, F., & Cheung, P. C. K. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.117258 · Cited by 97
Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities
Andersen, J. K., Miletić, H., & Hossain, J. A. (2022) · Cancers · doi:10.3390/cancers14051319 · Cited by 109
Berntsson, J., Eberhard, J., Nodin, B., Leandersson, K., Larsson, A. H., & Jirström, K. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1465165 · Cited by 62
Hu, B., Wang, Z., Zeng, H., Qi, Y., Chen, Y., Wang, T., Wang, J., Chang, Y., Bai, Q., Xia, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2254 · Cited by 99
Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy
Lee, Y., Shinn, J., Xu, C., Dobson, H. E., Neamati, N., & Moon, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-40270-5 · Cited by 99
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
IL-27, IL-30, and IL-35: A Cytokine Triumvirate in Cancer
Kourko, O., Seaver, K., Odoardi, N., Basta, S., & Gee, K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00969 · Cited by 96
Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment
Shen, L., Zhou, Y., He, H., Chen, W., Lenahan, C., Li, X., Deng, Y., Shao, A., & Huang, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8865791 · Cited by 105
Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
Choi, Y., Seok, S. H., Yoon, H. Y., Ryu, J. H., & Kwon, I. C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115306 · Cited by 100
Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91
“Recent breakthroughs have highlighted phagocytosis checkpoint axes which can be targeted to induce the anti-cancer functions of macrophages, such as the CD47-SIRPa phagocytosis axis (41), PD1-PDL1 axis (10), MHC I–LILRB1 axis (42), and CD24–Siglec-10 axis (43).”
BackgroundInfluentialMetabolic reprogramming in tumors: Contributions of the tumor microenvironment
Lane, A. N., Higashi, R. M., & Fan, T. W.-M. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2019.10.007 · Cited by 91
Himes, B. T., Peterson, T. E., de Mooij, T., Garcia, L. M. C., Jung, M.-Y., Uhm, S., Yan, D., Tyson, J., Jin-Lee, H. J., Parney, D., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa029 · Cited by 92
TRAF3/STAT6 axis regulates macrophage polarization and tumor progression
Shi, J., Liu, L., Song, D., Liu, W.-W., Chen, L., Wu, F., Wang, T., Liu, B., Cui, N., Qin, Y., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01194-1 · Cited by 105
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond
Lu, J., Ma, Y., Li, Q., Xu, Y., Xue, Y., & Xu, S. (2024) · Biomarker Research · doi:10.1186/s40364-024-00637-2 · Cited by 102
Moon, Y., Cho, H., Kim, J., Song, S., Park, J. Y., Min, J. Y., Han, E. H., Kim, Y., Seong, J., Shim, M. K., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202414146 · Cited by 111
Kim, M. J., Kim, K., Park, H. J., Kim, G.-R., Hong, K. H., Oh, J. H., Son, J., Park, D. J., Kim, D., Choi, J.-M., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01373-1 · Cited by 90
Targeting tumor‐associated macrophages: A potential treatment for solid tumors
Chen, Y., Jin, H., Song, Y., Huang, T., Cao, J., Tang, Q., & Zou, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30139 · Cited by 82
Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 99
Albonici, L., Giganti, M. G., Modesti, A., Manzari, V., & Bei, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122970 · Cited by 94
Immunotherapy via PD-L1–presenting biomaterials leads to long-term islet graft survival
Coronel, M. M., Martin, K. E., Hunckler, M. D., Barber, G., O’Neill, E. B., Medina, J. D., Opri, E., McClain, C. A., Batra, L., Weaver, J. D., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba5573 · Cited by 89
“Yet, recent reports negatively correlate signaling through the PD-1/PD-L1 axis with the phagocytic potential of macrophages (45).”
BackgroundMacrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
Luo, Z.-W., Liu, P.-P., Wang, Z.-X., Chen, C.-Y., & Xie, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586580 · Cited by 89
Zen, Y., Chen, Y., Jeng, Y., Tsai, H., & Yeh, M. M. (2020) · Histopathology · doi:10.1111/his.14000 · Cited by 83
Malignant transformation of oral leukoplakia is associated with macrophage polarization
Weber, M., Wehrhan, F., Baran, C., Agaimy, A., Büttner-Herold, M. J., Öztürk, H., Neubauer, K., Wickenhauser, C., Kesting, M. R., & Ries, J. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-019-02191-0 · Cited by 89
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 94
Zhang, J., Song, C., Tian, Y. F., & Yang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.802080 · Cited by 99
Role of macrophages in tumor progression and therapy (Review)
Xu, Y., Wang, X., Liu, L., Wang, J., Wu, J., & Sun, C. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5347 · Cited by 94
Liu, C., Xie, J., Lin, B., Tian, W., Wu, Y., Shan, X., Hong, L., Li, X., Liu, L., Jin, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202401061 · Cited by 103
Sato, R., Imamura, K., Sakata, S., Ikeda, T., Horio, Y., Iyama, S., Akaike, K., Hamada, S., Jodai, T., Nakashima, K., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060762 · Cited by 90
Nanotechnology-enhanced immunotherapy for metastatic cancer
Zhang, P., Meng, J., Li, Y., Chen, Y., Hou, Y., Tang, W., McHugh, K. J., & Jing, L. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100174 · Cited by 123
Yang, Z., Gao, J., Zheng, J., Han, J., Li, A., Liu, G., Sun, Y., Zhang, J., Chen, G., Xu, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01762-y · Cited by 96
Biology and therapeutic targeting of tumour‐associated macrophages
Beltraminelli, T., & De Palma, M. (2020) · The Journal of Pathology · doi:10.1002/path.5403 · Cited by 86
Tong, N., He, Z., Ma, Y., Wang, Z., Huang, Z., Cao, H., Xu, L., Zou, Y., Wang, W., Yi, C., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.706286 · Cited by 99
Li, J., Ye, Y., Liu, Z., Zhang, G., Dai, H., Li, J., Zhou, B., Li, Y., Zhao, Q., Huang, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00354-5 · Cited by 90
Xiao, L., Zhang, L., Guo, C., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2024) · 癌症:英文版 · doi:10.1002/cac2.12579 · Cited by 96
Guimarães, G. R., Maklouf, G. R., Teixeira, C. E., Santos, L. D. O., Tessarollo, N. G., de Toledo, N. E., Serain, A. F., de Lanna, C. A., Pretti, M. A. M., da Cruz, J. G. V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49916-4 · Cited by 97
Belgiovine, C., Digifico, E., Anfray, C., Ummarino, A., & Torres, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103226 · Cited by 90
Prognostic value and immunological role of PDCD1 gene in pan-cancer
Miao, Y., Wang, J., Li, Q., Quan, W., Wang, Y., Li, C., Wu, J., & Mi, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107080 · Cited by 97
Hu, Y., Manasrah, B. K., McGregor, S. M., Lera, R. F., Norman, R. X., Tucker, J. B., Scribano, C. M., Yan, R. E., Humayun, M., Wisinski, K. B., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0195 · Cited by 92
Deng, L. H., Qian, G., Zhang, S., Zheng, H., Fan, S., Lesinski, G. B., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. (2019) · Oncogene · doi:10.1038/s41388-019-0877-4 · Cited by 87
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 86
Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways
Taghiloo, S., & Asgarian‐Omran, H. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103164 · Cited by 93
Mechanisms of Immunosuppression in Colorectal Cancer
Zhang, Y., Rajput, A., Jin, N. Y., & Wang, J. (2020) · Cancers · doi:10.3390/cancers12123850 · Cited by 93
Zhang, X., Hu, L.-P., Yang, Q., Qin, W., Wang, X., Xu, C., Tian, G.-A., Yang, X., Yao, L.-L., Zhu, L., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01827-0 · Cited by 88
Ahirwar, D. K., Charan, M., Mishra, S., Verma, A. K., Shilo, K., Ramaswamy, B., & Ganju, R. K. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3909 · Cited by 91
Sakamoto, Y., Mima, K., Ishimoto, T., Ogata, Y., Imai, K., Miyamoto, Y., Akiyama, T., Daitoku, N., Hiyoshi, Y., Iwatsuki, M., et al. (2021) · Cancer Science · doi:10.1111/cas.15126 · Cited by 81
Tsuruta, A., Shiiba, Y., Matsunaga, N., Fujimoto, M., Yoshida, Y., Koyanagi, S., & Ohdo, S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0786 · Cited by 93
MAPK Signaling Pathway in Oral Squamous Cell Carcinoma: Biological Function and Targeted Therapy
Cheng, Y., Chen, J., Shi, Y., Fang, X., & Tang, Z. (2022) · Cancers · doi:10.3390/cancers14194625 · Cited by 80
Zhong, W., Lu, Y., Han, X., Yang, J., Qin, Z., Zhang, W., Yu, Z., Wu, B., Liu, S., Xu, W., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113224 · Cited by 95
PD-L1 and tumor-associated macrophages in de novo DLBCL
McCord, R., Bolen, C. R., Koeppen, H., Kadel, E. E., Oestergaard, M. Z., Nielsen, T. G., Sehn, L. H., & Venstrom, J. M. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018020602 · Cited by 85
Razak, S. A. A., Gazzali, A. M., Fisol, F. A., Abdulbaqi, I. M., Parumasivam, T., Mohtar, N., & Wahab, H. A. (2021) · Cancers · doi:10.3390/cancers13030400 · Cited by 88
The COX-2–PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas
Wei, J., Zhang, J., Wang, D., Cen, B., Lang, J. D., & DuBois, R. N. (2022) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-21-0572 · Cited by 91
Pernot, S., Évrard, S., & Khatib, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850856 · Cited by 98
Liu, Y., Li, X., Zhang, Y., Wang, H., Rong, X., Peng, J., He, L., & Peng, Y. (2019) · Oncogene · doi:10.1038/s41388-019-0952-x · Cited by 87
Tumor hijacks macrophages and microbiota through extracellular vesicles
Jiang, J., Mei, J., Ma, Y., Jiang, S., Zhang, J., Yi, S., Feng, C., Liu, Y., & Liu, Y. (2022) · Exploration · doi:10.1002/exp.20210144 · Cited by 91
Yang, H. D., Kim, H. S., Kim, S. Y., Na, M. J., Yang, G., Eun, J. W., Wang, H.-J., Cheong, J. Y., Park, W. S., & Nam, S. W. (2019) · Hepatology · doi:10.1002/hep.30657 · Cited by 85
Qiu, S., Deng, L., Liao, X., Nie, L., Qi, F., Jin, K., Tu, X., Zheng, X. S., Li, J., Liu, L., et al. (2019) · Cancer Science · doi:10.1111/cas.14078 · Cited by 89
Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?
Deligne, C., & Midwood, K. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620773 · Cited by 86
The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity
Wu, Z., Li, S., & Zhu, X. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682435 · Cited by 84
Macrophages as a “weapon” in anticancer cellular immunotherapy
Aminin, D. L., & Wang, Y. (2021) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12405 · Cited by 85
Li, J., Wang, S., Wang, N., Zheng, Y., Yang, B., Wang, X., Zhang, J., Pan, B., & Wang, Z. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00775-2 · Cited by 90
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 84
Zhang, D., Shi, R., Xiang, W., Kang, X., Tang, B., Li, C., Gao, L., Zhang, X., Zhang, L., Dai, R., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0117-y · Cited by 88
Cho, B. S., Lee, J., Won, Y., Duncan, D. I., Jin, R. C., Lee, J., Kwon, H. H., Park, G.-H., Yang, S. H., Park, B. C., et al. (2020) · Cosmetics · doi:10.3390/cosmetics7040090 · Cited by 77
Nanoplasmonic Sandwich Immunoassay for Tumor-Derived Exosome Detection and Exosomal PD-L1 Profiling
Wang, C., Huang, C.-H., Gao, Z., Shen, J., He, J., MacLachlan, A., Ma, C., Chang, Y., Yang, W. L., Cai, Y., et al. (2021) · ACS Sensors · doi:10.1021/acssensors.1c01101 · Cited by 81
Yu, K.-X., Yuan, W.-J., Wang, H.-Z., & Li, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03675-9 · Cited by 96
Lan, T., Gao, F., Cai, Y., Lv, Y., Zhu, J., Liu, H., Xie, S., Wan, H., He, H., Xie, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55577-0 · Cited by 93
Crosby, E. J., Wei, J., Yang, X. Y., Lei, G., Wang, T., Liu, C.-X., Agarwal, P., Korman, A. J., Morse, M. A., Gouin, K., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1421891 · Cited by 84
Schürch, C. M., Roelli, M. A., Forster, S., Wasmer, M.-H., Bruehl, F. K., Maire, R., Pancrazio, S. D., Ruepp, M., Giger, R., Perren, A. A., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0555 · Cited by 86
Immune-Related Adverse Events: Pneumonitis
Zhong, L., Altan, M., Shannon, V. R., & Sheshadri, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_13 · Cited by 86
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Qu, J., Mei, Q., Liu, L., Cheng, T., Wang, P., Chen, L., & Zhou, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992968 · Cited by 86
Tumor-associated macrophage-related strategies for glioma immunotherapy
Tang, F., Wang, Y., Zeng, Y., Xiao, A., Tong, A., & Xu, J. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00431-7 · Cited by 90
Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study
Iv, M., Samghabadi, P., Holdsworth, S. J., Gentles, A. J., Rezaii, P. G., Harsh, G. R., Li, G., Thomas, R. P., Moseley, M. E., Daldrup-Link, H. E., et al. (2018) · Radiology · doi:10.1148/radiol.2018181204 · Cited by 84
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
Chen, C., Hutzen, B. J., Wedekind, M. F., & Cripe, T. P. (2018) · Oncolytic Virotherapy · doi:10.2147/ov.s145532 · Cited by 88
Nanomedicine-based strategies to target and modulate the tumor microenvironment
Mendes, B. B., Sousa, D. P., Conniot, J., & Conde, J. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.001 · Cited by 88
SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis
Li, Y., Zhou, H., Liu, P., Lv, D., Shi, Y., Tang, B., Xu, J., Zhong, T., Xu, W., Zhang, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162870 · Cited by 82
Vanmeerbeek, I., Naulaerts, S., Sprooten, J., Laureano, R. S., Govaerts, J., Trotta, R., Pretto, S., Zhao, S., Cafarello, S. T., Verelst, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adm8660 · Cited by 83
Tumor-Associated Macrophages as Major Immunosuppressive Cells in the Tumor Microenvironment
Ghebremedhin, A., Athavale, D., Zhang, Y.-T. Y., Yao, X., Balch, C., & Song, S. (2024) · Cancers · doi:10.3390/cancers16193410 · Cited by 92
After cell death: the molecular machinery of efferocytosis
Moon, B., Yang, S., Moon, H., Lee, J., & Park, D. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01070-5 · Cited by 78
Metadata
- Authors
- Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., Ring, A. M., Connolly, A. J., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Yale University (US)
- Corresponding author
- Weissman, Irving L.
- ORCID
- Venue
- Nature
- Published
- 2017-05
- Volume
- 545
- Issue
- 7655
- Pages
- 495-499
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5931375
- OpenAlex
- W2615301036
- Cited by
- 2,247
- References
- 34
- Citations by year
- 2026: 167 · 2025: 261 · 2024: 303 · 2023: 298 · 2022: 309 · 2021: 299 · 2020: 264 · 2019: 158 · 2018: 135 · 2017: 51
- FWCI
- 75.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Science Foundation
- Cancer Research Institute
- A.P. Giannini Foundation
- Giannini Foundation of Agricultural Economics
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (155336)
- National Institutes of Health (1s10rr026780-01)
- National Cancer Institute (R01CA086017, P30CA124435)
- National Institute of General Medical Sciences (T32GM007365)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR050942)
- National Center for Research Resources (1S10RR02678001, 1S10RR026780, S10 RR026780)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- PD-1, tumour-associated macrophages, PD-L1, phagocytosis, immune checkpoint blockade, tumour immunity, cancer immunotherapy, tumour-infiltrating macrophages
- MeSH terms
- Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Neoplasm Staging, Phagocytosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.